{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-260421","form_type":"8-K","ticker":null,"cik":"0001556263","company_name":"Syros Pharmaceuticals, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.773359+00:00","generated_at":"2026-05-29T23:01:25.376160+00:00","sec_items":["1.02","2.04","2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Syros terminates QIAGEN pact, defaults on $43.7M loan, cuts 94% of staff, replaces CEO","bullets":["Phase 3 SELECT-MDS-1 trial failure triggers termination of QIAGEN companion diagnostic agreement.","Oxford Finance declares $43.7M immediately due; Syros pays $33.5M, plans forbearance negotiations.","Workforce reduced by ~94%; CEO Conley Chee, CFO Jason Haas, CMO David Roth terminated without cause.","Board members Andrew Oh, Srinivas Akkaraju, Deborah Dunsire, and others resign; Gerald Quirk appointed CEO.","Gerald Quirk, previously Chief Legal & Compliance Officer, becomes President & CEO effective Nov 22, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-260421","json":"https://secwatch.observer/filing/0001193125-24-260421.json","markdown":"https://secwatch.observer/filing/0001193125-24-260421.md","text":"https://secwatch.observer/filing/0001193125-24-260421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/d874889d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:01:25.376160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d1cef4109","claim":"Timothy Tyson resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"51ec353463","claim":"David Roth was terminated as Chief Medical Officer at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"533b53e43f","claim":"S. Gail Eckhardt resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5c4c0aa38d","claim":"Conley Chee resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"In addition, Mr. Chee resigned from the Board of Directors and all committees or subcommittees thereof, effective upon his termination of employment on November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6307ed2fc3","claim":"Deborah Dunsire resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6ad4df695f","claim":"Conley Chee was terminated as President and Chief Executive Officer at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"951dfade61","claim":"Srinivas Akkaraju resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ab44982532","claim":"Andrew M. Oh resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 12, 2024, Andrew M. Oh notified the Board of Directors of the Company of his resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e16dd5d4cf","claim":"Jason Haas was terminated as Chief Financial Officer at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e4a8fa00e3","claim":"Gerald Quirk was appointed as President and Chief Executive Officer at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, the Board of Directors appointed Gerald Quirk, Esq., currently the Company’s Chief Legal & Compliance Officer and Chief Business Officer, to serve as the Company’s President and Chief Executive Officer effective as of November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fe8ff1f3c5","claim":"Richard Young resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On November 15, 2024, Srinivas Akkaraju, M.D., Ph.D., Deborah Dunsire, M.D., S. Gail Eckhardt, M.D., Timonthy Tyson, and Richard Young, Ph.D., each notified the Board of Directors of such director’s resignation from the Board of Directors and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f4ad441419859db401181166335cc5ab14f3b9de","claim":"Syros Pharmaceuticals, Inc. announced a restructuring (approximately 94%).","evidence_excerpt":"On November 12, 2024, the Company’s authorized officers, with the endorsement of the Company’s Board of Directors, committed to implementing a reduction in workforce by approximately 94%.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Headcount","value":"approximately 94%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}